Compare Huntington Bancshares Incorporated (HBAN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Novavax Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B), while Novavax Inc trades at $12.83 (market cap $1.82B). The key difference: Huntington Bancshares Incorporated is far larger — about 17.1× Novavax Inc's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Novavax Inc for 59 Days on average.
| HBAN | NVAX | |
|---|---|---|
Market Cap | $31.04B | $1.82B |
Volume | 23,864,172 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $19.27 | $12.56 |
52-Week Low | $15.02 | $6.22 |
Typical Hold Time | 52 Days | 59 Days |
Enterprise Value | $49.57B | $1.39B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.28, up 0.73% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bearish technical signal with key support at $15 and resistance at $16, while fundamentals show a P/E of 11.82 and net income margin of 24.77%. Recent news highlights a cut in 2027 earnings outlook due to interest rate pressures, though the company maintains shareholder returns via dividends and buybacks.
The outlook for HBAN is cautious, with near-term headwinds from margin compression and loan growth challenges offset by a solid balance sheet and analyst consensus price target of $19.60. Risks include persistent interest rate pressures and competitive lending markets, but the stock offers value appeal with a dividend yield and institutional support.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
